At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 40 enrolled

Drug / intervention

Clonazepam +1 moredrug

Likely dose

Placebo 0.5mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02312908

NCT02312908Phase 2Completed

Compare CT.gov

Effect of Clonazepam on REM Sleep Behavior Disorder in Patients With Parkinsonism: a Prospective, Randomized, Double-blind and Placebo-controlled Trial

Seoul National University Hospital·interventional·Posted Dec 9, 2014·Updated Apr 25, 2016

In Brief

A Phase 2 clinical trial evaluating Clonazepam and Placebo for REM Sleep Behavior Disorder. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether clonazepam is effective and safe in the treatment of rapid eye movement behavior disorder (RBD) of patients with Parkinson's disease (PD).

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsREM Sleep Behavior Disorder

CountriesSouth Korea

CollaboratorsMinistry of Food and Drug Safety, Korea

Timeline

Phase 2CompletedFinished

201520162017201820192020202120222023202420252026

First PostedDec 2014

Enrollment StartMar 2015

Primary CompletionMar 2016

TodayJul 2026

First PostedDec 9, 2014

Enrollment StartMar 1, 2015

Primary CompletionMar 1, 2016

TodayJul 2, 2026

Enrollment to primary: 1 yearPosted 11.6 years ago

Interventions

Clonazepamdrug

For experimental treatment of RBD

Placebodrug

Placebo pill manufactured to mask clonazepam 0.5mg tablet